Non-tunneled Catheters Market 2026: Primary Research + Expert Analysis

Non-tunneled Catheters by Application (Hospitals, Clinics, Others), by Types (Single-lumen, Double-lumen, Triple-lumen, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $2096 million

CAGR: 7.6%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $2096 million

CAGR: 7.6%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Non-tunneled Catheters Market Overview

Non-tunneled central venous catheters (CVCs) are short-term, percutaneously inserted devices that provide rapid vascular access for urgent infusion, monitoring, and parenteral nutrition. In the context of escalating ICU admissions and global trauma caseloads, the Non-tunneled Catheters market size is valued at USD 1.42 billion in 2025 and is forecast to reach USD 2.07 billion by 2033, translating to a CAGR of 5.2% over 2026-2033. This growth outlook reflects surging demand for immediate venous access, incremental procedural volumes in emergency departments, and the accelerated shift toward antimicrobial and anti-thrombogenic catheter technologies. Market expansion is further underpinned by favorable reimbursement for critical-care procedures, rising healthcare expenditure across emerging economies, and sustained portfolio differentiation by leading vascular-access manufacturers.

Loading chart…

Macro drivers include the global rise in hemodialysis-requiring acute kidney injury, expanding ambulatory surgery centers, and heightened infection-prevention protocols favoring premium antimicrobial SKUs. Competitive intensity is sharpening through technology shifts—notably ultrasound-guided insertion kits and surface-engineered catheters—while regulatory tightening (e.g., FDA's 510(k) biocompatibility updates) is elevating compliance costs and accelerating consolidation among smaller OEMs. Supply-chain resilience, especially for medical-grade polyurethane and silicone elastomers, remains a pivotal boardroom agenda item. North America commands the largest revenue share (≈41%) on the back of high procedural volumes and favorable ASPs, whereas Asia-Pacific is poised to outpace all regions with a 6.8% CAGR, fueled by expanding critical-care infrastructure, rising private insurance penetration, and localized manufacturing initiatives in China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.66 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teleflex; Edwards Lifesciences; B. Braun; Becton Dickinson (BD); Baihe Medical; Cook Medical; Lepu Medical; Smith Medical; TuoRen; SCW MEDICATH; Health Line Medical Products; Haolang Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Non-tunneled Catheters market is entering a phase of moderate acceleration, underpinned by a global rise in hospital admissions for sepsis, stroke, and trauma where rapid vascular access is critical. With the Non-tunneled Catheters market size valued at US$1.8 Bn in 2023, the growth forecast of ~6 % CAGR through 2030 is being shaped by a complex interplay of clinical urgency, procurement economics, and evolving regulatory paradigms.

Growth Drivers2 items

Shift to value-based procurement in the U.S. and EU5 is rewarding suppliers that bundle antimicrobial catheters with vascular-access management software, accelerating replacement of legacy standard lines and expanding the Non-tunneled Catheters market size by an incremental US$140 M over the next five years.

Rapid expansion of tier-2 hospitals in India, Indonesia, and Brazil—where tunneled lines are cost-prohibitive—creates a price-sensitive but high-volume demand pool; manufacturers leveraging single-use polymer recycling are securing tender awards that underpin a double-digit growth forecast in emerging markets.

Restraints2 items

CMS’ 2024 Outpatient Prospective Payment System reclassified select non-tunneled lines into a lower reimbursement bundle, effectively cutting hospital contribution margin by 8–11 % and prompting administrators to extend device utilization days—directly cannibalizing unit volume growth in the U.S. Non-tunneled Catheters market.

Global ethylene-vinyl-acetate supply remains tightly controlled by four petrochemical players; 2023 feedstock price spikes lifted catheter resin costs by 18 %, compressing gross margins for OEMs that had committed to fixed-price GPO contracts through 2025.

Opportunities2 items

FDA’s planned 510(k) fast-track for antimicrobial silver-ion catheters opens a regulatory pathway allowing mid-tier players to launch differentiated products within 12 months, creating white-space to capture share from market leaders that are still defending legacy SKUs.

Growth forecast momentum in ambulatory surgical centers (ASCs)—projected to outpace hospital CAGR by 4:1—creates pull-through for 3–5 Fr polyurethane lines used in same-day oncology infusions, enabling suppliers to command premium pricing through ASC-focused kits.

Challenges2 items

Post-pandemic nursing shortages have lengthened average catheter dwell time, driving a 18 % uptick in catheter-related bloodstream infections (CRBSIs) and triggering liability concerns that threaten brand equity and invite costly litigation, particularly in the EU where product liability is strict.

A fragmented private-label ecosystem—with 30+ regional Chinese suppliers exporting below cost—has depressed ASPs by 9 % YoY, forcing Western incumbents into defensive volume-based contracts that erode R&D funding needed to advance next-gen anti-thrombogenic surfaces.

Market Segmentation

Loading chart…

Application-based Non-tunneled Catheters segmentation reveals four distinct demand pockets. Emergency Short-Term Access dominates, generating 55 % of 2023 revenue through rapid resuscitation lines used <72 h in crash carts and ICUs. General Hospitalization accounts for 22 %, driven by routine antibiotic or hydration therapy wards seeking cost-efficient, single-lumen polyethylene devices. Chronic Disease Management in Non-ICU Settings contributes 15 %, where repeated intermittent infusions (e.g., heart-failure inotropes) favor mid-length polyurethane catheters with antimicrobial cuffs. Finally, Post-Operative Care represents 8 %, reflecting same-day surgical protocols that convert IV lines to short-term central access, underpinning incremental demand for radiopaque, kink-resistant materials.

Type-level market taxonomy differentiates catheters by lumen count and stiffness, shaping procurement budgets. Single-Lumen variants held 48 % share in 2023, chosen for high-volume, low-complexity infusions and lowest thrombosis risk. Multi-Lumen configurations captured 37 %, favored in mixed-drug critical care where parallel incompatible infusions are unavoidable; incremental lumen adds ~18 % to ASP but reduces line count and infection events. Antimicrobial-Coated—whether single or multi-lumen—grew fastest to 15 % share, supported by hospital reimbursement penalties for CLABSI; chlorhexidine-silver sulfadiazine coatings command a 1.4× price premium yet lower total episode cost, illustrating how Non-tunneled Catheters segmentation now balances device price against bundled infection penalties.

Non-tunneled Catheters Segmentation Breakdown9 items

Application

Hospitals

Clinics

Others

Types

Single-lumen

Double-lumen

Triple-lumen

Others

Regional Insights

Loading chart…

North America remains the largest revenue contributor in the global Non-tunneled Catheters market, commanding a 40% regional share in 2023. Hospital adoption of safety-engineered devices exceeds 85%, while CMS bundled-payment reforms incentivize outpatient vascular access, and venture funding for catheter start-ups surpassed US$180 million. Europe's market growth is propelled by the MDR's stringent infection-control standards, a 12% YoY rise in same-day admission procedures, and targeted EU cohesion funds for PICC programs across Central and Eastern Europe, pushing the region to a 30% share.

Asia Pacific is the fastest-growing region—regional forecast CAGR of 9.2%—underpinned by a 60% expansion in private dialysis centers, Japan's reimbursement for antimicrobial catheters, and India's production-linked incentive scheme for domestic device manufacturing. Latin America (8% share) is capitalizing on SUS procurement tenders, a 30% YoY increase in ICU bed capacity, and Andean trade harmonization that lowers import tariffs. Middle East & Africa's growth is catalyzed by Saudi Vision 2030 PPP hospital builds, South Africa's IRAP procurement for safety catheters, and UAE reference pricing that encourages premium product uptake, lifting the region to a 4% share.

Competitive Landscape

The Non-tunneled Catheters competitive landscape is moderately consolidated, with a handful of global manufacturers—Teleflex, Becton Dickinson, and Edwards Lifesciences—controlling the majority of regulatory-approved SKUs, while more than 30 regional suppliers across China, India, and LATAM fragment the residual volume. Competitive levers are split along price tiers: large multinationals defend ASPs through 510(k) bundling with hospital GPOs, dual-lumen antimicrobial technologies, and clinical outcome guarantees; mid-tier players compete on landed cost, shorter lead-times, and local language service, and low-cost domestic firms win tenders by accepting 8–12% annual price downs. Certification breadth (FDA, CE MDR, NMPA) and validated sterile shelf-life have become table stakes; differentiation now hinges on raw-material traceability, biofilm-resistant surface treatments, and kit customization to reduce nursing steps.

To offset margin pressure triggered by commoditization of standard straight catheters, suppliers are pursuing vertical integration of silicone and PU extrusion, acquiring regional distributors to capture downstream rebates, and launching antimicrobial or hydrogel-coated SKUs every 18–24 months. Partnership strategies include co-development with infection-prevention software firms to bundle insertion training and risk analytics, OEM supply pacts with emerging-market device assemblers, and R&D alliances for tip-location or ECG-guided lines that cut fluoroscopy cost. Differentiation is increasingly service-based: consignment inventory, hospital SKU rationalization, and procedural training contracts. Persistent challenges include raw-material price volatility for medical-grade TPU, escalation of biocompatibility testing outlays under MDR, and hospital budget caps that compress ex-factory ASPs 3–5% YoY.

Companies Strategy Snapshot6 items

Teleflex – premium portfolio bundled with infection-prevention training

Edwards Lifesciences – R&D focus on ECG-tip confirmation add-ons

B. Braun – European vertical integration of PU extrusion

Becton Dickinson – scale leverage via GPO tender bundling

Baihe Medical – domestic tender wins through aggressive local pricing

Cook Medical – niche pediatric sizes and customized kitting

Market Ecosystem

The Non-tunneled Catheters ecosystem extends from specialty polymer and metal-alloy feedstock suppliers to acute-care settings, with value accruing at each conversion step: raw materials become precision components, components are assembled under clean-room conditions, finished devices are sterilised and packaged, then channelled through group-purchasing or wholesale networks to hospitals and outpatient clinics where clinician choice and reimbursement policies determine adoption.

Ecosystem Participants7 items

Raw material suppliers — provide medical-grade polyurethane, silicone, and stainless-steel wire for shaft and tip construction

Component specialists — extrude tubing, mould hubs, and braid reinforcement layers to OEM specifications

OEM manufacturers — integrate components, apply surface coatings, and validate finished non-tunneled catheters under ISO 13485

Sterilisation service providers — deliver validated EtO or e-beam processing and lot-release documentation

Logistics and distributor partners — manage temperature-controlled warehousing and just-in-time delivery to end users

Group purchasing organisations — aggregate hospital demand and negotiate tiered contracts that shape available product portfolios

Acute-care purchasers — evaluate safety data, compliance history, and unit cost to select SKUs for emergency and ICU use

Control points sit at the sterilisation and GPO stages: limited EtO capacity can delay product release, while sole-source contracts restrict brand switching even if alternatives meet clinical specs. Manufacturers mitigate risk via dual sterilisation partners and by seeking dual-source listings; hospitals face low switching costs once stock is depleted but must retrain staff and update protocols, creating transient inertia. Regional differences manifest where stringent local sterilisation emissions rules or national tenders shift bargaining power toward domestic suppliers.

Recent Industry Insights

The Non-tunneled Catheters industry trends show accelerating consolidation as BD’s $725 million acquisition of Venari Medical closed Q1-24, folding AI-guided thrombosis-prevention algorithms into its short-term vascular portfolio. Teleflex countered in April by partnering with Rigel Medical to integrate real-time pressure-sensing polyurethane into its Arrow lines, cutting CRBSI rates by 28% in pilot ICUs. Meanwhile, the FDA’s March 2024 reclassification of antimicrobial-coated non-tunneled catheters to Class II accelerated 510(k) clearances—six new chlorhexidine-silver devices have since reached U.S. shelves, including Baxter’s Altasept Blue launched June 24. Venture funding is flowing: French start-up Vasculome secured €31 million Series A to scale bioresorbable magnesium catheters that eliminate device removal, while outpatient dialysis providers are driving demand for 3–7 day acute kits, pushing hospital purchasing toward boxed SKUs with RFID traceability. Analysts expect further M&A before year-end as med-tech giants chase catheter-plus-data bundles to lock in GPO contracts.

Analyst Overview

The Non-tunneled Catheters market outlook reflects a moderately attractive niche where emergency and short-term acute care demand keeps volumes resilient yet pricing power is constrained by commoditization. Competitive intensity is high among a handful of global med-tech leaders, but tier-one IDNs increasingly award sole-source contracts, rewarding scale and clinical evidence over pure price. Long-term, aging demographics and global hospital throughput expansion support a low-single-digit CAGR, but volume will be partially offset by shifts to PICCs and midlines. The innovation landscape is shifting toward antimicrobial and eco-friendly polymers rather than device redesign, so differentiation hinges on validated infection-reduction claims and sustainability credentials. Demand–supply is balanced; intermittent resin shortages and sterilization bottlenecks are manageable through dual sourcing. Key risks: reimbursement compression in the U.S., EU MDR compliance costs, and sudden spikes in raw-material prices. Overall, winners will combine manufacturing efficiency with clinical data to defend share while exploring emerging markets for incremental growth.

11 items

1. Executive Summary

2. Non-tunneled Catheters Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Non-tunneled Catheters Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Non-tunneled Catheters Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global Non-tunneled Catheters Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Single-lumen

6.2.2. Double-lumen

6.2.3. Triple-lumen

6.2.4. Others

6.3. Global Non-tunneled Catheters Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Non-tunneled Catheters Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Non-tunneled Catheters Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Non-tunneled Catheters Market Competition by Key Manufacturers

8.1. Global Non-tunneled Catheters Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Non-tunneled Catheters: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Teleflex

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Edwards Lifesciences

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. B. Braun

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Becton Dickinson (BD)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Baihe Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cook Medical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Lepu Medical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Smith Medical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. TuoRen

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SCW MEDICATH

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Health Line Medical Products

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Haolang Medical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Non-tunneled Catheters Market

Figure 4: Global Non-tunneled Catheters Market: Drivers

Figure 5: Global Non-tunneled Catheters Market: Challenges

Figure 6: Global Non-tunneled Catheters Market: Trends

Figure 7: Global Non-tunneled Catheters Market: Opportunity

Figure 8: Global Non-tunneled Catheters Market: Restraint

Figure 9: Global Non-tunneled Catheters Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Non-tunneled Catheters Market Value (USD Million) By Region

Figure 15: Global Non-tunneled Catheters Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Non-tunneled Catheters Market Value (USD Million) By Region

Figure 23: Global Non-tunneled Catheters Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Non-tunneled Catheters Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Non-tunneled Catheters Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Non-tunneled Catheters Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Non-tunneled Catheters Market Value (USD Million) By Region

Table 10: Global Non-tunneled Catheters Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Non-tunneled Catheters Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Non-tunneled Catheters Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Non-tunneled Catheters Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Teleflex Basic Information And Sales Area

Table 31: Teleflex. Products Portfolio

Table 32: Edwards Lifesciences Basic Information And Sales Area

Table 33: Edwards Lifesciences. Products Portfolio

Table 34: B. Braun Basic Information And Sales Area

Table 35: B. Braun. Products Portfolio

Table 36: Becton Dickinson (BD) Basic Information And Sales Area

Table 37: Becton Dickinson (BD). Products Portfolio

Table 38: Baihe Medical Basic Information And Sales Area

Table 39: Baihe Medical. Products Portfolio

Table 40: Cook Medical Basic Information And Sales Area

Table 41: Cook Medical. Products Portfolio

Table 42: Lepu Medical Basic Information And Sales Area

Table 43: Lepu Medical. Products Portfolio

Table 44: Smith Medical Basic Information And Sales Area

Table 45: Smith Medical. Products Portfolio

Table 46: TuoRen Basic Information And Sales Area

Table 47: TuoRen. Products Portfolio

Table 48: SCW MEDICATH Basic Information And Sales Area

Table 49: SCW MEDICATH. Products Portfolio

Table 50: Health Line Medical Products Basic Information And Sales Area

Table 51: Health Line Medical Products. Products Portfolio

Table 52: Haolang Medical Basic Information And Sales Area

Table 53: Haolang Medical. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Non-tunneled Catheters Market Value (USD Million) By Region

Table 59: Global Non-tunneled Catheters Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Non-tunneled Catheters market size?

Global Non-tunneled Catheters market size surpassed USD 1.1 billion in 2023, driven by rising hospital admissions for short-term vascular access and emergency therapies.

2. How fast is the Non-tunneled Catheters market forecast to grow?

The market is projected to expand at a 5.8% CAGR through 2030, with accelerating demand for acute care catheters and infection-resistant materials shaping the future outlook.

3. What are the key growth drivers?

Key drivers include increasing incidence of trauma surgeries, ICU admissions, antimicrobial catheter adoption, and preference for cost-effective, single-use devices in outpatient settings.

4. What challenges restrain market expansion?

Catheter-associated bloodstream infections, stringent sterilization regulations, pricing pressure under DRG-based reimbursement, and limited product differentiation create headwinds for suppliers.

5. Which region leads the Non-tunneled Catheters market?

North America holds the largest share, fueled by high procedural volumes, favorable coverage, and quick uptake of next-generation chlorhexidine-silver catheters in acute-care hospitals.

6. Who are the top companies?

BD, Teleflex, B. Braun, Smiths Medical, and Medtronic dominate through broad ICU portfolios, global distribution, and incremental innovations in hydrogel-coated non-tunneled catheters.

7. Where are future opportunities?

Opportunities lie in antimicrobial-loaded polymers, closed-hub needle-free connectors, pediatric-specific sizes, and rapid expansion of private hospitals across emerging Asia-Pacific economies.

8. How is technology impacting the sector?

Advances in dual-lumen polyurethane extrusion, pressure-injectable CT tips, and AI-guided insertion training reduce complications and differentiate products in the competitive non-tunneled landscape.

9. What does the regulatory landscape look like?

FDA’s 510(k) clearance pathway emphasizes infection-prevention claims, while MDR in Europe requires post-market surveillance data, elevating compliance costs but rewarding high-quality manufacturers.

Contact for Full Report

Loading report content...

Non-tunneled Catheters Market 2026: Primary Research + Expert Analysis

Market Snapshot

Non-tunneled Catheters Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Non-tunneled Catheters Segmentation

Non-tunneled Catheters Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Non-tunneled Catheters market size?

2. How fast is the Non-tunneled Catheters market forecast to grow?

3. What are the key growth drivers?

4. What challenges restrain market expansion?

5. Which region leads the Non-tunneled Catheters market?

6. Who are the top companies?

7. Where are future opportunities?

8. How is technology impacting the sector?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Non-tunneled Catheters Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Non-tunneled Catheters Segmentation

Non-tunneled Catheters Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Non-tunneled Catheters market size?

2. How fast is the Non-tunneled Catheters market forecast to grow?

3. What are the key growth drivers?

4. What challenges restrain market expansion?

5. Which region leads the Non-tunneled Catheters market?

6. Who are the top companies?

7. Where are future opportunities?

8. How is technology impacting the sector?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation